T1 and T2 mapping to detect chronic inflammation in cardiac magnetic resonance imaging in heart failure with reduced ejection fraction.
| Title: | T1 and T2 mapping to detect chronic inflammation in cardiac magnetic resonance imaging in heart failure with reduced ejection fraction. |
|---|---|
| Authors: | Emrich T; Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.; German Center for Cardiovascular Research (DZHK), partner site Rhine-Main, Mainz, Germany.; Hahn F; Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.; Fleischmann D; Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.; Halfmann MC; Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.; Düber C; Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.; Varga-Szemes A; Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC, USA.; Escher F; IKDT Institut Kardiale Diagnostik und Therapie GmbH, Berlin, Germany.; Department of Cardiology, Campus Virchow-Klinikum, Charité-University Medicine Berlin, Berlin, Germany.; Pefani E; Center for Cardiology, Cardiology 1, University Medical Center Mainz, Mainz, Germany.; Münzel T; German Center for Cardiovascular Research (DZHK), partner site Rhine-Main, Mainz, Germany.; Center for Cardiology, Cardiology 1, University Medical Center Mainz, Mainz, Germany.; Schultheiss HP; IKDT Institut Kardiale Diagnostik und Therapie GmbH, Berlin, Germany.; Kreitner KF; Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany.; Wenzel P; German Center for Cardiovascular Research (DZHK), partner site Rhine-Main, Mainz, Germany.; Center for Cardiology, Cardiology 1, University Medical Center Mainz, Mainz, Germany.; Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany. |
| Source: | ESC heart failure [ESC Heart Fail] 2020 Oct; Vol. 7 (5), pp. 2544-2552. Date of Electronic Publication: 2020 Aug 13. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Oxford] : John Wiley & Sons Ltd on behalf of the European Society of Cardiology, [2014]- |
| MeSH Terms: | Heart Failure*/diagnosis; Inflammation/diagnosis ; Humans ; Magnetic Resonance Imaging ; Magnetic Resonance Imaging, Cine ; Myocardium ; Predictive Value of Tests ; Retrospective Studies ; Stroke Volume ; Ventricular Function, Left |
| Abstract: | Aims: The purpose of this retrospective single-centre study was to evaluate the non-invasive detection of endomyocardial biopsy (EMB)-established chronic myocardial inflammation in patients with heart failure with reduced ejection fraction (HFrEF) using T1 and T2 mapping.; Methods and Results: The study population consisted of 52 retrospectively identified HFrEF patients who underwent EMB and cardiac magnetic resonance imaging at 3 Tesla. EMB was defined according to the position statement of the European Society of Cardiology and served as reference to identify inflammation in all patients. A control group of healthy volunteers with prior cardiac magnetic resonance imaging studies (n = 58) was also identified. Global and segmental T1 and T2 values as well as septal measurements and tissue heterogeneity parameters were calculated. Out of the 52 patients with HFrEF, 33 patients had myocardial inflammation detected by EMB, while 19 patients were EMB negative for inflammation. Mean left ventricular ejection fraction was 31% in both groups (P = 0.97). Global T1 and T2 values in HFrEF patients were significantly higher compared with healthy controls (T1 1275 ± 69 ms vs. 1,175 ± 44 ms, P < 0.001; T2 40.0 ± 3.4 ms vs. 37.9 ± 1.6 ms, P < 0.001). The distribution of T1 and T2 values between patients with and without EMB-proven chronic myocardial inflammation was not statistically different when regarding global (T1 1292 ± 71 ms vs. 1266 ± 67 ms, P=0.26; T2 40.0 ± 2.6 ms vs. 40.0 ± 3.9 ms, P=1.0), septal (T1 1299 ± 63 ms vs. 1289 ± 76 ms, P=0.76; T2 40.1 ± 3.5 ms vs 40.0 ± 6.4 ms, P=0.49) or maximum segmental values (T1 1414 ± 111 ms vs. 1363 ± 88 ms, P=0.15; T2 47.3 ± 5.2 ms vs. 48.8 ± 11.8 ms, P=0.53). Mean absolute deviation of segmental T1 and T2 values and log-transformed pixel-wise standard deviation as parameters of tissue heterogeneity did not reveal statistical significant differences between inflammation-positive and inflammation-negative HFrEF patients (all P > 0.4).; Conclusions: Conventionally performed quantitative T1 and T2 mapping values significantly correlated with prevalence of HFrEF but did not discriminate HFrEF patients with or without chronic myocardial inflammation in our cohort. This suggests that EMB is the preferred method to detect chronic myocardial inflammation in HFrEF.; (© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.) |
| References: | ESC Heart Fail. 2020 Oct;7(5):2544-2552. (PMID: 32790159); J Am Coll Cardiol. 2016 Apr 19;67(15):1800-1811. (PMID: 27081020); Eur Heart J. 2007 Dec;28(24):3076-93. (PMID: 17959624); Lancet. 2010 Feb 27;375(9716):752-62. (PMID: 20189027); Theranostics. 2019 Feb 12;9(5):1303-1322. (PMID: 30867832); J Hepatol. 2019 Jun;70(6):1133-1144. (PMID: 30876945); Korean J Radiol. 2017 Jan-Feb;18(1):113-131. (PMID: 28096723); Eur Heart J. 2009 Aug;30(16):1995-2002. (PMID: 19556262); Circulation. 2002 Jan 29;105(4):539-42. (PMID: 11815441); Radiology. 2019 Sep;292(3):608-617. (PMID: 31361205); Circulation. 2018 Mar 6;137(10):993-995. (PMID: 29506992); Circulation. 2010 Aug 31;122(9):900-9. (PMID: 20713901); J Cardiovasc Magn Reson. 2013 Oct 14;15:92. (PMID: 24124732); Catheter Cardiovasc Interv. 2015 Oct;86(4):761-5. (PMID: 25586731); Nat Rev Cardiol. 2013 Sep;10(9):531-47. (PMID: 23900355); Circulation. 2015 Oct 27;132(17):1667-78. (PMID: 26503749); Circulation. 1989 Sep;80(3):564-72. (PMID: 2766509); JACC Cardiovasc Imaging. 2012 May;5(5):513-24. (PMID: 22595159); Cardiovasc Pathol. 2012 Jul-Aug;21(4):245-74. (PMID: 22137237); Circulation. 2008 Oct 21;118(17):1722-8. (PMID: 18838566); Heart Fail Rev. 2017 Jul;22(4):431-440. (PMID: 28497231); ESC Heart Fail. 2018 Aug;5(4):630-641. (PMID: 29745463); Circ Res. 2017 Sep 15;121(7):722-730. (PMID: 28912179); Eur Heart J Cardiovasc Imaging. 2018 May 1;19(5):574-582. (PMID: 29136120); JACC Cardiovasc Imaging. 2013 Oct;6(10):1048-1058. (PMID: 24011774); Circulation. 1999 Mar 2;99(8):1091-100. (PMID: 10051305); Int J Cardiovasc Imaging. 2014 Jun;30 Suppl 1:65-72. (PMID: 24715436); J Cardiovasc Magn Reson. 2014 Jan 04;16:2. (PMID: 24387626); Eur J Heart Fail. 2014 Oct;16(10):1066-72. (PMID: 25163698); J Cardiovasc Magn Reson. 2015 Dec 23;17:115. (PMID: 26700020); J Am Coll Cardiol. 1997 Feb;29(2):429-34. (PMID: 9015000); JACC Cardiovasc Imaging. 2016 Jan;9(1):67-81. (PMID: 26762877); Cancer Med. 2017 Jan;6(1):89-99. (PMID: 27891815); Int J Cardiol Heart Vasc. 2019 Sep 07;25:100422. (PMID: 31517037); Med Sci Monit. 2002 May;8(5):MT59-71. (PMID: 12011783); Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d. (PMID: 23824828); Eur Heart J. 2016 Jun 14;37(23):1850-8. (PMID: 26792875) |
| Grant Information: | BMBF 01EO1503 International Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie |
| Contributed Indexing: | Keywords: CMR; DCM phenotype; HFrEF; Inflammation; Mapping |
| Entry Date(s): | Date Created: 20200814 Date Completed: 20210621 Latest Revision: 20210621 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7524213 |
| DOI: | 10.1002/ehf2.12830 |
| PMID: | 32790159 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't